

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Karen Koch et al

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: December 14, 2001

Examiner: To be assigned

For: Hormone Composition

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE SPECIFICATION:

At page 1, after the title, insert

--CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. 119 of Danish application PA 2000 01890 filed on December 15, 2000; PA 2000 01891 filed December 15, 2000; and PA 2000 01892 filed on December 15, 2000, and of US application nos. 60/260,182 filed January 5, 2001, 60/260,183 filed on January 5, 2001 and 60/260,184 filed on January 5, 2001, the contents of which are fully incorporated herein by reference.—

IN THE CLAIMS:

Cancel claims 1-28 and 33 without prejudice or disclaimer.

REMARKS

Entry of this amendment is respectfully requested.


In this amendment, claims 1-28 and 33 have been cancelled without prejudice.

Claims 29-32 and 34-53 are pending and at issue.

It is respectfully submitted that the claims are in condition for allowance, and a determination to that effect is earnestly solicited.

Respectfully submitted,

Date: December 14, 2001



Reza Green, Reg. No. 38,475
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE